Dyne Therapeutics, Inc. (DYN) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
DYN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Dyne Therapeutics, Inc. (DYN) trades at a price-to-earnings ratio of -5.4x, with a stock price of $18.84 and trailing twelve-month earnings per share of $-3.47.
Compared to the Healthcare sector median P/E of 22.1x, DYN trades at a 125% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, DYN trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DYN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DYN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 30.3Lowest | -Best | -19% | |
| $40B | 130.0 | -Best | +207%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See DYN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DYN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DYN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDYN — Frequently Asked Questions
Quick answers to the most common questions about buying DYN stock.
Is DYN stock overvalued or undervalued?
DYN current P/E: -5.4x. 5-year average P/E: N/A. Percentile: N/A.
How does DYN's valuation compare to peers?
Dyne Therapeutics, Inc. P/E of -5.4x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is DYN's PEG ratio?
DYN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.